Premium
Adenocarcinoma of the pancreas: A multimodality approach—A single surgeon's experience (1979—1988)
Author(s) -
Schuricht Alan L.,
Barbot Donna J.,
Mohiuddin Mohammed,
Rosato Francis E.
Publication year - 1991
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930480111
Subject(s) - medicine , surgery , adenocarcinoma , stage (stratigraphy) , radiation therapy , retrospective cohort study , pancreas , chemotherapy , brachytherapy , carcinoma , cancer , paleontology , biology
Abstract A retrospective review of a single surgeon's experience with adenocarcinoma of the pancreas was performed. One hundred‐one patients were treated over a 10‐year period from 1979 to 1988. Seven patients underwent potentially curative resections and 28 patients presented with metastatic (stage IV) disease. Sixty‐four patients had locally advanced and unresectable primary lesions. A total of 51 patients received I‐125 seed implantation. There was no statistically significant difference in morbidity (33% vs. 30%) or mortality (6% vs. 8%) between patients receiving I‐125 implantation and those undergoing palliative surgical procedures without implantation. Operative mortality was highest in patients presenting with stage IV lesions (11%). In those patients with locally advanced and unresectable carcinomas, there was a nonsignificant increase in survival (12.8 mo vs. 10.7 mo) in those receiving intraoperative I‐125 implants when compared to those who did not when both groups received postoperative adjuvant chemotherapy and external beam radiotherapy. Based on these encouraging results, it is concluded that I‐125 implantation can be performed safely and shows a trend toward improving long‐term survivorship in patients with locally advanced pancreatic carcinoma when used in conjunction with chemotherapy and external beam radiation.